Menstrual and reproductive factors and risk of lung cancer among Chinese women,

Eastern Gansu Province, 1994-1998

Alina V. Brenner^{1,*}, Zuoyuan Wang², Ruth A. Kleinerman¹, Shujie Lei², Catherine Metayer¹, Wenlan Wang², Jay H. Lubin¹

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, EPS, Bethesda, MD 20892, USA

²Laboratory of Industrial Hygiene, Ministry of Public Health, 2 Xinkang Street, Deshengmenwai, Beijing 100088, People's Republic of China

*Address correspondence: Dr. Alina V. Brenner, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd. MSC 7362, Bethesda, MD 20892 – 7362

Tel: 001 (301) 496-6600 Fax: 001 (301) 402-0207 e-mail: brennera@mail.nih.gov

Running title: female lung cancer and menstrual history

List of abbreviations:

Odds ratios (OR)

Environmental tobacco smoking (ETS)

Abstract

There are suggestions that women have higher relative risks of lung cancer than men given similar levels of tobacco exposure, implying that sex-related hormones may influence lung cancer risk. We evaluated the association between lung cancer risk and menstrual and reproductive factors on a subset of self-responding females in a population based case-control study in Eastern Gansu Province, China, 1994-1998. The analysis included 109 incident lung cancer cases and 435 controls selected from the census list and frequency matched to cases on age and prefecture. Odds ratios were lower for later ages at menarche (trend, P = 0.015) and later ages at menopause (trend, P = 0.074). Despite limitations, these findings suggest a possible role of hormones in the etiology of lung cancer in females.

Key words: female; lung neoplasms; risk factors; history, reproductive; menstruation.

There are suggestions that women may have a higher relative risk of lung cancer than men given similar levels of tobacco exposure (1-4). Also, it appears that worldwide lung cancer is more common among lifetime non-smoking women (5, 6). If true, this implies that women may be more susceptible to lung cancer and sex-related hormones may influence its risk.

The lung is usually not considered a target organ for sex hormones; however, specific estrogen and progesterone receptors are distributed in normal lung tissue and some lung cancers (7-10). Animal experiments have demonstrated that sex hormones directly alter fetal lung differentiation (11) and have affected the incidence of pulmonary neoplasms in adulthood (12). In addition, estrogens have been shown to influence the development of carcinoma in other organs such as pancreas (13), stomach (14,15) and colon (15). Epidemiological data on the role of female hormones in lung cancer etiology have been mixed. Several studies have demonstrated that the use of hormone replacement therapy was associated with an increased risk of lung cancer (16-18). Further, some menstrual and reproductive factors including age at menarche and natural menopause, length and total number of menstrual cycles have been associated with lung cancer, primarily adenocarcinoma, but the patterns are inconsistent (17-22). Finally, one prospective study has found clusters of cancers of the reproductive system and the lung in families, implying possible common risk factors (23).

The present investigation analyzed the association between the risk of lung cancer and a variety of menstrual and reproductive factors, using interview data from a population-based case-control study conducted in Eastern Gansu Province, China. The study area is predominantly rural, and subjects have little exposure to industrial sources

of air pollution and a low prevalence of smoking, thus minimizing the influence of major confounders for lung cancer.

Materials and methods

Case ascertainment

We conducted a population-based case-control study of incident lung cancer in males and females in Pingliang and Qingyang, two rural prefectures in Eastern Gansu Province, China, described in detail elsewhere (24). Briefly, there were 230 incident lung cancer cases of females, aged 30-75 years, diagnosed between January, 1994, and April, 1998. Cases were identified retrospectively (1994-1995) and prospectively (1996-1998) from two prefecture hospitals, a company hospital located at a nearby oilfield, 15 county hospitals, and local clinics. We also reviewed records from special anti-tuberculosis reporting stations in the prefectures and large near by cities, such as Lanzhou, Xi'an, and Yinchuan for lung cancer diagnosed in residents of the two prefectures. All lung cancer diagnoses were reviewed by an expert panel that consisted of two oncologists, two radiologists, and one pathologist. The panel considered all the available diagnostic evidence for the particular case, including medical records, radiological images, pathology reports and/or slides.

We excluded 118 deceased cases whose information derived from surrogate interviews, in order to ensure accuracy of the reported information. Additionally, three female cases could not be interviewed in person and were excluded, resulting in 109 cases. Histological confirmation was available for 38 out of 109 living cases, a confirmation level consistent with other Chinese studies (25). Of these, 16 were small cell carcinomas, 14 were squamous cell carcinomas, 1 was adenocarcinoma, and 7 were characterized as pulmonary neoplasms without any additional specification.

Controls were randomly sampled from the population census list of the two prefectures and frequency matched to cases by gender, within 5-year age group and prefecture in a ratio of 2:1 (24). A total of 455 female controls were eligible. Fourteen controls were deceased at the time of the interview and six could not be interviewed. Since controls were frequency matched on age, all 435 interviewed controls were included in the analysis.

Interview

Personal interviews were conducted by trained interviewers using a structured questionnaire. The section on menstrual and reproductive factors included information on age at menarche, length of menstrual cycle, number of days of menstrual flow, number of pregnancies, age at first live birth, parity, age at menopause, type of menopause, use of oral contraceptives, history of irregular menstrual cycles, and type of gynecological surgeries. Data were also collected on sociodemographic characteristics, amount of time spent at home, housing characteristics, lifetime smoking habits, including smoking by other members of the household (24), type of fuel used in homes, diet and cooking practices, occupation, pesticide use, and medical histories.

Statistical analysis

Odds ratios (OR) were used as the measure of association between lung cancer and risk factors of interest. Unconditional, multivariate logistic regression models were carried out using the SAS program (26) to adjust ORs for confounding factors (reference age, prefecture, socioeconomic status, active smoking, environmental tobacco smoke (ETS) among never-smokers, the amount of coal used in homes for cooking and heating, cooking oil use, and previous pulmonary diseases). Reference age was defined as the age at diagnosis for a case and the age at interview for a control. A woman was considered post-menopausal if she did not have regular periods for the last 12 months. Assuming an equal period of postpartum amenorrhea, the total number of menstrual cycles up to the reference date was calculated as:

 $T = [(A1 - A2) \times 365 - B \times 280] / C,$

where A1 = age at last/most recent menstrual period;

A2 = age at menarche;

B = number of live births;

C = average cycle length.

Results

Table 1 summarizes the sociodemographic characteristics and exposure to tobacco smoke of the participants. Subjects were comparable on reference age (although there was a slightly higher proportion of younger cases), prefecture, and marital status. Cases had higher socioeconomic status as measured by a higher proportion of education above the primary level, a higher income, and greater ownership of goods such as a color television set. There was no excess risk of lung cancer among smokers (ever smoker vs. never smoker), but the proportion of smokers (10%), as well as the amount (mean = 4 cigarettes per day), duration of smoking (mean = 17 years) was low by Western standards. Finally, cases tended to have higher exposure to ETS during childhood than controls, although the difference was not significant.

Table 2 summarizes the relationships between a variety of menstrual and reproductive factors and lung cancer risk. ORs for lung cancer were lower for later ages at menarche (trend, P = 0.015) and later ages at natural menopause (trend, P = 0.074). ORs were elevated for later ages at first live birth, although the trend was not significant (trend, P = 0.980). There was little suggestion of an association between lung cancer and length of the menstrual cycle, days of menstrual flow, number of live births, and total number of menstrual cycles up to the reference date. Adjustment for a variety of variables (socioeconomic status, active smoking, ETS among non-smokers, amount of coal, cooking oil use, and previous pulmonary diseases) did not alter these results (not shown).

The use of oral contraceptives, as well as history of gynecological surgeries, was rare (less than three percent) in the study population and could not be analyzed.

Discussion

In this population-based case-control study of lung cancer in a rural area of China, we found a statistically significant decrease in lung cancer risk with later ages at menarche and a marginally significant decrease in lung cancer risk with later ages at natural menopause. ORs for later ages at first live birth were elevated, but the trend was not significant.

Several methodological issues arise in interpreting our results. The present analysis was limited to self-responders which raises the possibility of selection bias (while minimizing the possibility of reporting bias by excluding next-of-kin responders for deceased cases). We evaluated the possibility of selection bias by conducting a survival analysis for all 230 cases based on time from disease incidence to death. None of the variables (socioeconomic status, active smoking, ETS, amount of coal, cooking oil use, history of previous pulmonary diseases) was a significant predictor of the time from diagnosis to death, after adjustment for calendar-year of diagnosis, age at diagnosis of lung cancer, and prefecture. This suggests minimal selection bias. There was also concern about accuracy of lung cancer diagnosis, since histological verification was available for only 35 percent of the cases. The survival time did not depend on the availability of pathological evidence (about 1 year for confirmed and suspected cases) and results remained unchanged when the data were limited to the pathologically confirmed cases. Residual confounding is always possible. Adjustment for active smoking and restricting data to never smokers, and adjustment for a variety of known confounding variables had no effect on the risk estimates. However, because of limited statistical power, our results should be interpreted with caution.

The strengths of the present study include a population-based design, low prevalence of smoking among women, rural population with limited exposure to industrial pollution, and detailed information on a variety of risk factors for lung cancer.

Overall, there have been few epidemiological studies conducted on reproductive and menstrual history and risk of lung cancer (Table 3). The results have been inconsistent among the studies and relative to a pattern one might expect based on breast cancer data. One U.S. study showed an increased risk with late menarche (18) in contrast to our findings. Three studies (17-19) suggested an increase in the risk of lung cancer with later age at natural menopause, whereas two others (18), including the present study, found an inverse association with age at natural menopause. Ours was the only study to suggest an increased risk with later ages at first live birth, while another study demonstrated an increased risk with number of live births (22). Finally, one study demonstrated an association of adenocarcinoma and shorter menstrual cycles (19) and another reported that cases with squamous cell lung cancer had a higher lifetime number of menstrual cycles than controls, but cases with adenocarcinoma had a shorter period of menstrual flow (21).

A biological involvement of sex hormones in pathogenesis of lung cancer, particularly adenocarcinoma, seems plausible based on the presence of specific estrogen and progesterone receptors in normal and some malignant lung tissues (7-10), animal experiments (11-12), and effects of sex hormones on other non-target tumors (13-15). However, the exact mechanism and whether it is similar to other hormone-dependent tumors is unknown. If sex hormones indeed influence the development of lung cancer, then the association between reproductive factors and lung cancer is likely to be weak, which might explain the inconsistency of the epidemiological results given the limited number of studies. In addition, any association of reproductive factors may occur with a

particular histological type or pattern of receptor expression in lung cancer. If so, then risk estimates would be diluted when all lung cancer types are analyzed together as in this study. Finally, hormones may not be carcinogenic themselves but rather modify the effects of other exposures important in the development of lung cancer.

Conclusion

In summary, the results of this study suggest a possible role of female hormones in the etiology of lung cancer. However, given the limitations of our study, these results warrant cautious interpretation.

Acknowledgements

This work was supported by a contract between the United States National Cancer Institute (NO1-CP-50509) and the Laboratory of Industrial Hygiene, Beijing, China. We thank Ms. Margaret Pacious and Ms. Regina Hur, Westat Inc., for data management and programming support. We appreciate data collection efforts accomplished by Shurong Zhang, Bing Shang, Ying Xia, Wenlan Wang, Jisheng Cao, Shujie Lei of the Laboratory of Industrial Hygiene, Ministry of Public Health, People's Republic of China. We are also grateful to members of the expert review panel, Drs. Jiguo Shi, Yuelan Kang, Fuhui Du, Datong Zhao, Yucheng Wang, for reviewing lung cancer diagnoses.

- 1. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst, 1996;88:183-92.
- 2. Ernster VL. Female lung cancer. Annu Rev Public Health, 1996;17:97-114.
- 3. Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol, 1993;138:281-93.
- 4. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst, 1984;73:383-9.
- 5. Siegfried JM. Women and lung cancer: does oestrogen play a role? Lancet Oncol, 2001;85:506-13.
- Koo LC, Ho JH. Worldwide epidemiological patterns of lung cancer in nonsmokers.
 Int J Epidemiol, 1990;19:S14-S23.
- 7. Chaudhuri PK, Thomas PA, Walker MJ, et al. Steroid receptors in human lung cancer cytosols. Cancer Lett, 1982;16:327-32.
- 8. Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res, 1990;50:6632-5.
- Canver CC, Memoli VA, Vanderveer PL, Dingivan CA, Mentzer RM. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg, 1994;108:153-7.

- 10. Beattie CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer.

 Cancer Res, 1985;45:4206-14.
- 11. Khosla SS, Brehier A, Eisenfeld AJ, et al. Influence of sex hormones on lung maturation in the fetal rabbit. Biochim Biophys Acta, 1983; 750:112-26.
- 12. Noronha RF, Goodall CM. Enhancement by testosterone of dimethylnitrosamine carcinogenesis in lung, liver and kidney of inbred NZR/Gd female rats. Carcinogenesis, 1983;4:613-6.
- 13. Greenway B, Iqbal MJ, Johnson PJ, Williams RR. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J, 1983;283:751-3.
- 14. Kitaoka H, Sex hormone dependency and endocrine therapy in diffuse carcinoma of the stomach (in Japanese). Gan To Kagaku Ryoho, 1983;10:2453-60.
- 15. Harrison JD, Watson S, Morris DL. The effect of sex hormones and tamoxifen on the growth of human gastric and colorectal cancer cell lines. Cancer, 1989;63:2148-51.
- 16. Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer, 1989;44:833-9.
- 17. Taioli E, Wynder EL, Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst, 1994;86:869-70.
- 18. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res, 1988; 48:7279-84.

- 19. Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer, 1987;40:604-9.
- 20. Wu-Williams AH, Dai XD, Blot W, et al. Lung cancer among women in north-east China. Br J Cancer, 1990;62:982-7.
- 21. Liao ML, Wang JH, Wang HM, et al. A study of the association between squamous cell carcinoma and adenocarcinoma in the lung, and history of menstruation in Shanghai women, China. Lung Cancer, 1996;14:S215-S221.
- 22. Zhou BS, Wang TJ, Guan P, Wu JM. Indoor air pollution and pulmonary adenocarcinoma among females: a case-control study in Shenyang, China. Oncol Rep, 2000;7:1253-59.
- 23. Sellers TA, Potter JD, Folsom AR. Association of incident lung cancer with family history of female reproductive cancers: the Iowa Women's Health Study. Genet Epidemiol, 1991;8:199-208.
- 24. Wang L, Lubin JH, Zhang SR, et al. Lung cancer and environmental tobacco smoke in a non-industrial area of China. Int J Cancer, 2000;88:139-45.
- 25. Liu Q, Sasco AJ, Riboli E, Hu MX. Indoor air pollution and lung cancer in Guangzhou, People's Republic of China. Am J Epidemiol, 1993;137:145-54.
- 26. SAS/STAT User's Guide, version 8. Cary, NC: SAS Institute Inc, 1999.

TABLE 1 - COMPARISON OF FEMALE LUNG CANCER CASES AND CONTROLS BY SOCIODEMOGRAPHIC CHARACTERISTICS AND EXPOSURE TO TOBACCO SMOKE, GANSU PROVINCE, CHINA, 1994-1998

Characteristic	Cases ¹ (n=109)	Controls ¹ (n=435)	OR ²	95% CI ³	P value ⁴
Age, years					
<45	21	51	1.0^{5}		0.245
45-54	38	162	0.57	0.31, 1.07	
55-64	34	144	0.58	0.30, 1.09	
65+	16	78	0.50	0.24, 1.07	
Prefecture					
Qingyang	48	180	1.0^{5}		0.903
Pingliang	61	255	0.97	0.63, 1.50	
Education					
Primary or less	95	415	1.0^{5}		0.019
Tech/vocation	14	18	3.0	1.40, 6.49	
College and above	0	2	NA	,	
Income, yuan/year					
< 2,000	21	106	1.0^{5}		0.107
2,000-2,999	15	86	0.96	0.46, 2.01	
3,000-4,399	32	110	1.7	0.88, 3.15	
4,400+	41	125	1.8	0.98, 3.24	
Number of color TVs					
None	71	352	1.0^{5}		< 0.001
At least one	38	81	2.5	1.53, 3.94	
Marital status					
Married	94	371	1.0^{5}		0.814
Widowed	15	64	0.92	0.47, 1.80	
Smoking status					
Never smoker	98	389	1.0^{5}		0.981
Ever smoker	11	45	1.0	0.50, 2.05	
Environmental tobacco smoke (ETS) in childhood, pack-years					
<1	30	153	1.0^{5}		0.149
1-9	41	159	1.3	0.76, 2.17	· · · · · ·
10+	16	39	2.0	1.00, 4.19	

¹Numbers may not add up to column totals because of missing data. - ²Odds ratio. - ³95% confidence interval. - ⁴Test of independence, adjusted for reference age and prefecture. ⁵Referent.

TABLE 2 - ODDS RATIOS (OR) AND 95% CONFIDENCE INTERVALS (95% CI) FOR DEVELOPING LUNG CANCER ACCODING TO THE MENSTRUAL AND REPRODUCTIVE HISTORY AMONG FEMALES, GANSU PROVINCE, CHINA 1994-1998

Age at menarche, years <15	Menstrual/	Cases	Controls	OR ²	95% CI	P for
Age at menarche, years	reproductive	$(N=109)^1$	$(N=435)^1$			trend
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$						
15-16 39 188 0.52 0.31, 0.88 17+ 28 130 0.54 0.31, 0.96 Age at natural menopause, years 4 <45 16 60 1.00 3 0.74 45-49 37 136 0.95 0.49, 1.86 50+ 11 94 0.39 0.17, 0.92 Average length of the menstrual cycle, days <28 21 102 1.00 3 0.560 28-29 55 174 1.55 0.88, 2.72 30+ 27 145 0.91 0.48, 1.71 Average length of the menstrual flow, days ≤3 20 75 1.00 3 0.690 4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies 5 1-2 14 49 1.00 3 0.450 3-4 0.41, 1.70 Number of pregnancies 5 1-2 14 49 1.00 3 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years 5 ≤18 22 124 1.00 3 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years 5 ≤18 22 124 1.00 3 0.89, 2.64 2.3+ 2.3 82 1.46 0.75, 2.84 Number of live births 5 1-2 23 74 1.00 3 0.89, 2.64 2.3+ 2.3 82 1.46 0.75, 2.84 Number of menstrual cycles up to the reference date <300 21 70 1.00 3 0.83 3-44 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 3 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	-			2		
Age at natural menopause, years 4						0.015
Age at natural menopause, years 4 <45						
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	17+	28	130	0.54	0.31, 0.96	
45-49 37 136 0.95 0.49, 1.86 50+ 11 94 0.39 0.17, 0.92 Average length of the menstrual cycle, days <28 21 102 1.00³ 0.560 28-29 55 174 1.55 0.88, 2.72 30+ 27 145 0.91 0.48, 1.71 Average length of the menstrual flow, days ≤3 20 75 1.00³ 0.690 4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies⁵ 1-2 14 49 1.00³ 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years⁵ ≤18 22 124 1.00³ 0.28, 1.68 Age at first live birth, years⁵ ≤18 22 124 1.00³ 0.28, 1.68 Age at first live births, years⁵ ≤18 22 124 1.00³ 0.980 19-22 63 225 1.53 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births⁵ 1-2 23 74 1.00³ 0.980 2.94 19-22 63 225 1.53 0.89, 2.64 2.3+ 23 82 1.46 0.75, 2.84 Number of menstrual cycles up to the reference date <300 21 70 1.00³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	Age at natural menop	ause, years ⁴				
45-49 37 136 0.95 0.49, 1.86 50+ 11 94 0.39 0.17, 0.92 Average length of the menstrual cycle, days <28 21 102 1.00³ 0.560 28-29 55 174 1.55 0.88, 2.72 30+ 27 145 0.91 0.48, 1.71 Average length of the menstrual flow, days ≤3 20 75 1.00³ 0.690 4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies⁵ 1-2 14 49 1.00³ 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years⁵ ≤18 22 124 1.00³ 0.28, 1.68 Age at first live birth, years⁵ ≤18 22 124 1.00³ 0.28, 1.68 Age at first live births, years⁵ ≤18 22 124 1.00³ 0.980 19-22 63 225 1.53 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births⁵ 1-2 23 74 1.00³ 0.980 2.94 19-22 63 225 1.53 0.89, 2.64 2.3+ 23 82 1.46 0.75, 2.84 Number of menstrual cycles up to the reference date <300 21 70 1.00³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	<45	16	60	1.00^{3}		0.074
Average length of the menstrual cycle, days $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	45-49	37	136		0.49, 1.86	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	50+	11	94	0.39	0.17, 0.92	
28-29 55 174 1.55 0.88, 2.72 30+ 27 145 0.91 0.48, 1.71 Average length of the menstrual flow, days ≤3 20 75 1.00 ³ 0.690 4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies ⁵ 1-2 14 49 1.00 ³ 0.450 0.450 0.450 0.450 0.28, 1.68 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years ⁵ ≤18 22 124 1.00 ³ 0.89, 2.64 0.99 0.28, 1.68 Age at first live birth birth, years ⁵ ≤18 22 124 1.00 ³ 0.89, 2.64 0.99 0.28, 1.68 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.89, 2.64 0.75, 2.84 Number of live births ⁵ 1-2 13 74 1.00 ³ 0.89, 2.64 0.75, 2.84 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	Average length of the	menstrual cy	cle, days			
28-29 55 174 1.55 0.88, 2.72 30+ 27 145 0.91 0.48, 1.71 Average length of the menstrual flow, days ≤3 20 75 1.00 ³ 0.690 4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies ⁵ 1-2 14 49 1.00 ³ 0.450 0.450 0.450 0.450 0.49 0.53, 1.66 102 0.69 0.28, 1.68 Age at first live birth, years ⁵ ≤18 22 124 1.00 ³ 0.28, 1.68 Age at first live birth, years ⁵ ≤18 22 124 1.00 ³ 0.89, 2.64 2.3+ 2.3 82 1.46 0.75, 2.84 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.89, 2.64 2.3+ 2.3 82 1.46 0.75, 2.84 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 0.809 0.809 0.809 0.809 0.809 0.909	<28	21	102	1.00^{3}		0.560
30+ 27 145 0.91 0.48, 1.71 Average length of the menstrual flow, days ≤3 20 75 1.00 ³ 0.690 4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies ⁵ 1-2 14 49 1.00 ³ 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years ⁵ ≤18 22 124 1.00 ³ 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	28-29	55	174		0.88, 2.72	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	30+	27	145	0.91		
4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies ⁵ 1-2 14 49 1.00 ³ 0.450 3.4 41 151 1.09 0.54, 2.20 5.6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years ⁵ ≤18 22 124 1.00 ³ 0.89, 2.64 2.3+ 2.3 82 1.46 0.75, 2.84 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.83, 3.4 45 196 0.83 0.46, 1.50 5.6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	Average length of th	e menstrual f	low, days			
4-5 62 254 0.94 0.53, 1.66 6+ 20 95 0.84 0.41, 1.70 Number of pregnancies ⁵ 1-2 14 49 1.00 ³ 0.450 3.4 41 151 1.09 0.54, 2.20 5.6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years ⁵ ≤18 22 124 1.00 ³ 0.89, 2.64 2.3+ 2.3 82 1.46 0.75, 2.84 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.83, 3.4 45 196 0.83 0.46, 1.50 5.6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	≤3	20	75	1.00^{3}		0.690
Number of pregnancies ⁵ 1-2 14 49 1.00 ³ 0.450 3-4 41 151 1.09 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years ⁵ ≤ 18 22 124 1.00 ³ 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.83 3-4 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date < 300 21 70 1.00 ³ 0.809 $300-349$ 21 94 0.86 0.42, 1.74 $350-399$ 0.809		62	254		0.53, 1.66	
1-2 14 49 1.00³ 0.54, 2.20 3.4 41 151 1.09 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years⁵ ≤18 22 124 1.00³ 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births⁵ 1-2 23 74 1.00³ 0.83, 2.64 23+ 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63			95			
$3-4$ 41 151 1.09 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years 5 ≤18 22 124 1.00 3 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births 5 $1-2$ 23 74 1.00 3 0.833 3-4 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 3 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	Number of pregnanci	es ⁵				
$3-4$ 41 151 1.09 0.54, 2.20 5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years 5 ≤18 22 124 1.00 3 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births 5 $1-2$ 23 74 1.00 3 0.833 3-4 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 3 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	1-2	14	49	1.00^{3}		0.450
5-6 37 129 1.23 0.58, 2.61 7+ 16 102 0.69 0.28, 1.68 Age at first live birth, years ⁵ ≤18 22 124 1.00 ³ 0.89, 2.64 23+ 23 82 1.46 0.75, 2.84 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.833 3.4 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	3-4	41	151		0.54, 2.20	
Age at first live birth, years 5 $ \leq 18 \qquad 22 \qquad 124 \qquad 1.00^3 \qquad 0.980 $ $ 19-22 \qquad 63 \qquad 225 \qquad 1.53 \qquad 0.89, 2.64 $ $ 23+ \qquad 23 \qquad 82 \qquad 1.46 \qquad 0.75, 2.84 $ Number of live births 5 $ 1-2 \qquad 23 \qquad 74 \qquad 1.00^3 \qquad 0.833 $ $ 3-4 \qquad 45 \qquad 196 \qquad 0.83 \qquad 0.46, 1.50 $ $ 5-6 \qquad 29 \qquad 103 \qquad 1.14 \qquad 0.58, 2.24 $ $ 7+ \qquad 11 \qquad 58 \qquad 0.81 \qquad 0.34, 1.95 $ Number of menstrual cycles up to the reference date $ <300 \qquad 21 \qquad 70 \qquad 1.00^3 \qquad 0.809 $ $ 300-349 \qquad 21 \qquad 94 \qquad 0.86 \qquad 0.42, 1.74 $ $ 350-399 \qquad 33 \qquad 103 \qquad 1.32 \qquad 0.66, 2.63 $	5-6	37	129	1.23		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	7+	16	102	0.69	0.28, 1.68	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Age at first live birth,	years ⁵				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			124	1.003		0.980
23+ 23 82 1.46 0.75, 2.84 Number of live births ⁵ 1-2 23 74 1.00 ³ 0.833 3-4 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63					0.89, 2.64	0.500
$\begin{array}{cccccccccccccccccccccccccccccccccccc$						
3-4 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	Number of live births	5			,	
3-4 45 196 0.83 0.46, 1.50 5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63	1-2	23	74	1.00^{3}		0.833
5-6 29 103 1.14 0.58, 2.24 7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63					0.46, 1.50	
7+ 11 58 0.81 0.34, 1.95 Number of menstrual cycles up to the reference date <300 21 70 1.00 ³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63						
 <300 21 70 1.00³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63 						
 <300 21 70 1.00³ 0.809 300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63 	Number of menstrual	cycles up to	the reference	date		
300-349 21 94 0.86 0.42, 1.74 350-399 33 103 1.32 0.66, 2.63		-				0.809
350-399 33 103 1.32 0.66, 2.63					0.42, 1.74	
·						
100 20 101 0.00, 1.01	400+	25	134	0.79	0.38, 1.61	

¹Numbers may not add up to column totals because of missing data.-²ORs adjusted for reference age and prefecture.-³Referent.-⁴2 cases and 4 controls in the surgical menopause and 43 cases and 141 pre-menopausal controls were excluded from the analysis.-⁵4 nulliparious controls and 1 case with missing data were excluded from the analysis.

TABLE 3 - SUMMARY TABLE OF CASE-CONTROL STUDIES ON SELECTED MENSTRUAL AND REPRODUCTIVE FACTORS AND LUNG CANCER RISK

ALE	٦.	CHINCEN MISIN			
Refere	Referent study	Study area	Cases/Controls	Findings	Adjustment factors
(17)	Taioli E, Wynder EL, 1994 ¹	8 cities, USA	180/303	Age at menopause, years (<40, 41-49, 50+): 0.3 (0.1, 0.8), 0.8 (0.5, 1.4), 1.0	Smoking, age at diagnosis, years of education, body mass index, type of menopause (natural or surgical, radiation)
(18)	Wu AH, Yu MC, Thomas DC, et al., 1988 ¹	Los Angeles County, USA	336/336	Age at menarche, years (≤11, 12, 13, 14, 15+): 1.0, 1.1 (0.6, 1.9), 1.4 (0.8, 2.4), 1.7 (0.9, 3.1), 1.3 (0.7, 2.5) p for trend = 0.13 Age at natural menopause, years (≤48, 49-51, 52+): 1.0, 1.0 (0.4, 2.3), 0.6 (0.3, 1.4) p for trend = 0.26	Pack-years of smoking, years since smoking stopped, and depth of inhalation
(61)	Gao YT, Blot WJ, Zheng W, et al., 1987	Shanghai, China	672/735	Age at natural menopause for women 50+ years ¹ : 1.3 (0.9, 1.7) ² Total number of menstrual cycles (among women 55+ years in a natural menopause): increased risk ¹ Length of menstrual cycle, days (<26, 26-29, 30-33, >33): 2.2 (1.3, 3.7), 1.6 (1.0, 2.7), 1.6 (1.0, 2.6), 1.0	Age, education, smoking, and regularity of menstruation
(20)	Wu-Williams AH, Dai XD, Blot W, et al., 1990	Harbin, Shenyang, China	965/959	Age at natural menopause, years (<45, 45-49, 50-54, 55+): 1.0, 1.7 (1.2, 2.4), 1.3 (0.9, 1.8), 1.7 (1.0, 3.2)	Age, education, personal smoking, and study area
(21)	Liao Ml, Wang JH, Wang HM, et al., 1996	Shanghai, China	162 ¹ /19 ³ /187	Total number of menstrual cycles 3 : case mean = 453.2, control mean = 413.3 $p < 0.05^4$ Menstrual flow, days 1 : case mean=4.85, controls mean = 5.29 $p < 0.01^4$	Not applicable
(22)	Zhou B, Wang T, Guan P, Wu JM, 2000	Shenyang, China	2T/12T	Age at menarche, years (<16, 16+): 0.64 (0.31, 1.30), 1.0 Length of menstrual cycle, days (<30, 30+): 1.12 (0.40, 3.10), 1.0 Number of live births (0-1, 2, 3, 4+): 1.0, 0.97 (0.12, 4.91), 1.39 (0.23, 8.52), 2.32 (0.45, 12.02) p for trend = 0.04	None Income, eye irritation from smoke, history of lung cancer
	Present study	Gansu Province, China	109/435	Age at menarche, years (<15 , 15-16, 17+): 1.0, 0.52 (0.3, 10.88), 0.54 (0.31, 0.96) p for trend = 0.015 Age at natural menopause, years (<45 , 45-49, 50+): 1.0, 0.95 (0.49, 1.86), 0.39 (0.17, 0.92) p for trend = 0.074 Age at first live birth, years (\le 18, 19-22, 23+): 1.0, 1.53 (0.89, 2.64), 1.46 (0.75, 2.84) p for trend = 0.980	Age, prefecture Further adjustment for socioeconomic status, active smoking, ETS among non- smokers, amount of coal, and previous pulmonary diseases had no effect
		Adenoca	rcinoma -2 Odds	Adenocarcinoma - Odds ratio (95% confidence interval) - Squamous carcinoma - Test for homogeneity of variance	r homogeneity of wariance

¹Adenocarcinoma.-² Odds ratio (95% confidence interval).-³Squamous carcinoma.-⁴Test for homogeneity of variance.